Most VEXAS pts have pulm involvement on HRCT. Pulmonary manifestations of VEXAS are nonspecific and characterized predominantly by inflammatory parenchymal involvement. Abs 1569 #ACR22 @RheumNow https://t.co/7AB3b9e7Lt https://t.co/ikhQMEu5GA

Sarilumab demonstrated efficacy in difficult to treat GC resistant PMR patients. Abs 1543 #ACR22 @RheumNow https://t.co/TCo5g5i1qh https://t.co/tZOhvvuhpY

Does lifestyle impact Tx. response? #Abstr 1510 looked at effect of lifestyle on TNFi response in #axSpA - The study found higher BMI (obese, overweight) and smoking were less likely to respond to TNFi - Important to discuss lifestyle when starting tx. @RheumNow #ACR22 https://t.co/z98DFMLxu3

Refractory cystoid macular edema assoc'd w/ Bechet's uveitis can be effectively treated either with ADA, IFX or TCZ. Abs 1564 #ACR22 @RheumNow https://t.co/WcEI4d0Cl5 https://t.co/Tk0T41coog

ACR2022 Topic Panels https://t.co/0cto8DE7P5

Industry Abstract Previews of #ACR22 The pharmaceutical companies will showcase their featured clinical trials and abstracts at #ACR22. These are their best studies for you to review and evaluate as part of your to-do list. https://t.co/8fBJmT1cXG https://t.co/r7H5sqELPo

Abs 1417 finds physicians prefer ABA over TNFi for RF/ACPA+ pts w/ higher disease severity, older age, the presence of extra-articular manifestations, and comorbidities such as heart failure. My question: Trouble getting it first line? #ACR22 @RheumNow https://t.co/tlFMgjgDNM https://t.co/ukoeLgSSUd

ATOM study, Abs 1314, greater proportion of men with OP on abaloparatide vs placebo met the definition of a >3% responder at the LS, TH, and FN. #ACR22 @RheumNow https://t.co/q6gcX5Azts https://t.co/WEjqbl14ZN